Clinical Study

Ds8201-A-U301- A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of Ds-8201A, An Anti-Her2-Antibody Drug Conjugate (Adc), Versus Treatment Of Investigator's Choice For Her2-Positive, Unresectable And/Or Metastatic Breast Cancer Subje

Posted Date: Oct 1, 2019

  • Investigator: Mahmoud Charif
  • Specialties: Breast Cancer, Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to compare the progression-free survival (PFS) benefit of trastuzumab deruxtecan to investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1.

Criteria:

To Be Eligible You Must Be Diagnosed With Metastatic Or Unresectable Breast Cancer, >18 Years Of Age, No Uncontrolled Cardiovascular Disease, Nonpregnant And Nonbreastfeeding

Keywords:

Breast, Cancer, Oncology

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.